Chicago-based Zuckerman Investment Group increased its Henry Schein position by 72,040 shares in the third quarter. The overall position value went up by about $3.38 million from the previous period.

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conference in January: J.P. Morgan's Healthcare Investor Conference on Tuesday, January 13, 2026, at 3:00 p.m. PST / 6:00 p.m. EST, at The Westin St. Francis hotel in San Francisco. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.c.

Assenagon Asset Management S.A. decreased its holdings in Henry Schein, Inc. (NASDAQ: HSIC) by 52.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,480 shares of the company's stock after selling 23,586 shares during the period. Assenagon Asset Management

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) (the “Company”), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that it expects to appoint the Company's next CEO by mid-January 2026. Philip A. Laskawy, Lead Director for Henry Schein said, “We are pleased with the progress we have made in our search for Henry Schein's next CEO. The search process is nearing completion but will not be finalized before year.

Stock futures are quietly lower as investors unpack previously delayed GDP data for the third quarter

Henry Schein (NASDAQ: HSIC - Get Free Report) and McKesson (NYSE: MCK - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations. Valuation and Earnings This table compares Henry Schein and

Arrowstreet Capital Limited Partnership grew its stake in Henry Schein, Inc. (NASDAQ: HSIC) by 80.7% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 289,051 shares of the company's stock after purchasing an additional 129,077 shares during the period. Arrowstreet Capital

Henry Schein stands out as the largest global provider of healthcare products and services for office-based dental and medical practitioners, with a strong market share. HSIC continues to deliver solid growth, reporting Q3 revenue up 5.2% year-over-year and improved profitability across all segments, driven by internal growth and targeted programs. Management anticipates ongoing revenue and EBITDA growth, supported by demographic trends, increased healthcare access, and technological advancements like AI in dental care.

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?

Henry Schein, Inc. (HSIC) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript